“Pharma bro” Martin Shkreli was ordered to pay $64.6 million in profits and was banned for life from the pharmaceutical industry for an infamous episode several years ago in which his company purchased an old, lifesaving medicine and then boosted the price by 4,000% overnight.
The decision follows a trial last month in which Shkreli, a former hedge fund manager who quickly became reviled for his smug responses to an outraged public, was accused by a group of federal and state authorities for stifling competition. Also last month, his former company settled the same charges by agreeing to pay $40 million, and his former business partner, Kevin Mulleady, was banned from the industry for seven years.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
